Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases
Ding, C (2008) Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opinion on Biological Therapy, 8 (11). pp. 1805-1814.
|PDF - Full text restricted - Requires a PDF viewer|
Official URL: http://dx.doi.org/10.1517/147125220.127.116.115
B lymphocyte stimulator (BLyS) is a factor determining the survival of B cells, and elevated levels in serum or locally have been observed in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients. Belimumab (LymphoStat-B), a human monoclonal antibody that inhibits BlyS, was developed for the treatment of these diseases. OBJECTIVE: To summarize preclinical development, efficacy and safety of belimumab in treatment of RA and SLE. METHODS: Articles found in a PubMed search and data presented in abstract form at international conferences up to August 2008 are described. RESULTS/CONCLUSIONS: Belimumab was well tolerated in treatment of RA over 24 weeks and SLE over 3 years. It significantly decreased rheumatoid factor (RF) levels, and modestly reduced symptoms of RA, especially in some subgroups such as patients with high disease activity, positive RF and no anti-TNF treatment experience. It also significantly reduced symptoms of SLE, and decreased anti-double-stranded DNA autoantibodies among patients with positive baseline anti-double-stranded DNA or antinuclear antibodies during a long-period treatment. These results suggest that careful patient selection is necessary to achieve optimal outcomes.
|Additional Information:||Copyright © 2009 Informa plc
|Keywords:||BLyS Belimumab autoimmune
|Deposited By:||Ms Emma Stubbs|
|Deposited On:||03 Mar 2009 10:20|
|Last Modified:||03 Mar 2009 10:20|
|ePrint Statistics:||View statistics for this ePrint|
Repository Staff Only: item control page